Press Room

Webinar Series: Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management

Start
Tuesday, February 28, 2023 - 16:00
End
Thursday, April 20, 2023 - 17:00
Location: online
Webinar Series Spray Drying - SEM image of a particle in a dark green background

Hovione presents a new comprehensive three-part webinar series on "Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management" starting February 28, 2023.



Over the course of this series, Hovione experts will guide you through the complete journey of amorphous solid dispersions (ASDs), starting from the early formulation stage to process development and scale-up, and finally to commercial reality and lifecycle management of ASDs. 

As an experienced manufacturer of ASDs by spray drying for the pharmaceutical industry, Hovione will be able to share its extensive knowledge and experience. Furthermore, the featured experts will be available to answer your questions during a live Q&A.

 

Key Learnings for the Webinar Series

  • Gain knowledge on designing a successful formulation for Amorphous Solid Dispersions produced by Spray Drying
  • Discover how to develop a robust process at lab scale and assure a successful scale-up
  • Learn how to use a model-based methodology to establish the design space and a commercial process
  • Understand what to consider during the Lifecycle Management of a commercial Amorphous Solid Dispersion by Spray Drying 

 

SESSION 1 (On-demand)

Evaluating the Best Formulations for Amorphous Solid Dispersions by Spray Drying

Register Now to join us | Hovione

 

SESSION 2 (On-demand)

ASDs by Spray Drying: Process Development & Scale-Up

Register Now to join us | Hovione

 

SESSION 3 (On-demand)

Commercial Reality and Lifecycle Management of ASDs

Register Now to join us | Hovione

 

 

Do you have a challenging project?

get in touch with us click here | Hovione

Schedule your individual meeting at the upcoming tradeshows and conferences in Berlin, Boston, Orlando, Barcelona, Delhi or Edinburgh.

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026